Abvc biopharma receives notice of allowance from us patent and trademark office for abv-1504 used to treat major depressive disorder (mdd)

Fremont, ca, nov. 07, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that on october 20, 2022, it received a notice of allowance for abv-1504 from the us patent and trademark office.
ABVC Ratings Summary
ABVC Quant Ranking